In today’s recent session, 2.22 million shares of the Apellis Pharmaceuticals Inc (NASDAQ:APLS) have been traded, and its beta is 0.87. Most recently the company’s share price was $28.85, and it changed around $2.67 or 10.20% from the last close, which brings the market valuation of the company to $3.59B. APLS at last check was trading at a discount to its 52-week high of $73.80, offering almost -155.81% off that amount. The share price’s 52-week low was $24.34, which indicates that the recent value has risen by an impressive 15.63% since then. We note from Apellis Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 4.49 million shares, with the 3-month average coming to 2.64 million.
Apellis Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.59. If we narrow it down even further, the data shows that 0 out of 21 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 6 recommended APLS as a Hold, whereas 11 deemed it a Buy, and 0 rated it as Underweight. Apellis Pharmaceuticals Inc is expected to report earnings per share of -0.37 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Apellis Pharmaceuticals Inc (NASDAQ:APLS) trade information
Instantly APLS has been showing a green trend so far today with a performance of 10.20% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 30.65 on recent trading dayincreased the stock’s daily price by 5.87%. The company’s shares are currently down -51.80% year-to-date, but still down -1.40% over the last five days. On the other hand, Apellis Pharmaceuticals Inc (NASDAQ:APLS) is 7.33% up in the 30-day period. We can see from the shorts that 20.79 million shares have been sold at a short interest cover period of 7.13 day(s).
The consensus price target as assigned by Wall Street analysts is $76, which translates to bulls needing to increase their stock price by 62.04% from its current value. Analyst projections state that APLS is forecast to be at a low of $39 and a high of $113.
Apellis Pharmaceuticals Inc (APLS) estimates and forecasts
Apellis Pharmaceuticals Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -32.21 percent over the past six months and at a 61.80% annual growth rate that is well above the industry average of 17.80%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 49.28% in revenue this quarter, and will report an increase of 19.40% in the next quarter. The year-over-year growth rate is expected to be 91.68%, up from the previous year.
Consensus estimates provided by 18 financial analysts predict the company will bring in an average of 191.2M in revenue for the current quarter. 9 analysts expect Apellis Pharmaceuticals Inc to make 193.43M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 146.38M and 172.32M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 30.62%. Forecasts for the next quarter put sales growth at 12.25%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.70%. Apellis Pharmaceuticals Inc earnings are expected to increase by 62.30% in 2024, but the outlook is positive 33.30% per year for the next five years.
APLS Dividends
Apellis Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Feb-25.
Apellis Pharmaceuticals Inc (NASDAQ:APLS)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 13.98% of Apellis Pharmaceuticals Inc shares, and 97.43% of them are in the hands of institutional investors. The stock currently has a share float of 113.26%. Apellis Pharmaceuticals Inc stock is held by 378.0 institutions, with WELLINGTON MANAGEMENT GROUP LLP being the largest institutional investor. By 2024-06-30, it held 13.2269% of the shares, which is about 16.39 million shares worth $628.67 million.
ECOR1 CAPITAL, LLC, with 9.3681% or 11.61 million shares worth $445.26 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
